Olmesardipin Mylan Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesardipin Mylan Plus is a combination antihypertensive that addresses several pathways involved in blood pressure regulation.

• Hypertension: Provides additive blood pressure reduction when monotherapy is insufficient.
• Resistant hypertension: Helps achieve target pressures in patients who have not responded to two or more antihypertensive agents.
• Hypertensive patients with edema: The amlodipine component mitigates calcium‑channel‑mediated vasodilation while hydrochlorothiazide adds diuretic effect.

• The formulation combines three mechanisms: olmesartan medoxomil blocks angiotensin II type‑1 receptors, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, promoting arterial relaxation; and hydrochlorothiazide reduces plasma volume by inhibiting sodium‑chloride reabsorption in the distal convoluted tubule, together producing a synergistic antihypertensive effect.

Adverse reactions may occur with any antihypertensive combination. Monitoring for side effects is recommended.

Common Side Effects

• Dizziness: Light‑headed sensation, especially after standing.
• Peripheral edema: Swelling of ankles or feet.
• Headache: Mild to moderate intensity.
• Fatigue: General feeling of tiredness.
• Increased urination: Due to diuretic action.
• Flushing: Warm sensation, often transient.

Serious or Rare Side Effects

• Angio‑edema: Swelling of face, lips, or throat requiring immediate care.
• Severe hypotension: Marked drop in blood pressure with fainting risk.
• Electrolyte imbalance: Abnormal potassium or sodium levels.
• Acute kidney injury: Reduced renal function, especially in volume‑depleted patients.

Before initiating therapy, clinicians should evaluate patient history and laboratory parameters.

• Renal function: Assess creatinine clearance, adjust if impaired.
• Hepatic impairment: Use caution; monitor liver enzymes.
• Electrolytes: Check potassium and sodium levels regularly.
• Pregnancy: Contraindicated in the second and third trimesters; avoid unless benefits outweigh risks.
• Concomitant drugs: Review for potential interactions, especially other antihypertensives.
• Store below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Olmesardipin Mylan Plus may interact with several medication classes. Awareness of major and moderate interactions helps optimise safety.

Major Interactions (Avoid)

• Aliskiren (dual renin‑angiotensin blockade) – risk of hyperkalemia and renal dysfunction.
• Potassium‑sparing diuretics or supplements – may cause dangerous hyperkalemia.
• Lithium – increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive effect and affect renal function.
• Other antihypertensives (beta‑blockers, ACE inhibitors) – risk of additive hypotension.
• CYP3A4 inhibitors (e.g., itraconazole) – can raise amlodipine concentrations.